Navigation Links
New study shows benefit of early therapy in HIV-infected infants

Antiretroviral therapy (ART) for infants born with HIV infection may be most effective when given in their first five months of life, according to a study published in the April 1 issue of The Journal of Infectious Diseases, now available online.

Uncertainty over when to start antiretroviral treatment in children infected with HIV from their mothers revolves around balancing the benefits of preventing disease progression and the risks and costs of life-long therapy begun within months of birth. Policies on when to start ART vary across Europe. Up to this point, the effect of age on clinical outcome has been difficult to assess because CD4 cell counts--an immunological indicator of HIV progression--experience considerable age-related variation.

However, Marie-Louise Newell, MD, and her colleagues in the European Collaborative Study developed a way to standardize CD4 cell counts in relation to age, and thus better evaluate immune status. They call this age-adjusted CD4 cell count the "z-score." Based on data collected over the past 20 years on infected children born to HIV-1 infected women, the investigators concluded that "children who started their most potent ART between 5 months and 5 years of age were almost 60 percent less likely to attain a 20 percent increase in their CD4 cell count z-score at any time, compared to children who started treatment before 5 months."

However, the authors did not find an association between early age at initiation and an increased likelihood of sustaining CD4 cell level recovery. They found that the risk of subsequent deterioration was similar for children initiating treatment in all age groups.

Still, because initiating effective antiretroviral therapy before 5 months of age was strongly associated with more rapid improvement in CD4 cell count, the authors conclude it should be strongly considered in the management of infants infected with HIV.

The authors declared they had no conflicts of interest to disclose.


Source:Infectious Diseases Society of America

Related biology news :

1. Bioartificial kidney under study at MCG
2. W.M. Keck Foundation funds study of friendly microbes
3. Yellowstone microbes fueled by hydrogen, according to U. of Colorado study
4. Genome-wide mouse study yields link to human leukemia
5. Clam embryo study shows pollutant mixture adversely affects nerve cell development
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Same mutation aided evolution in many fish species, Stanford study finds
8. Sequencing of marine bacterium will help study of cell communication
9. Genetically modified rice in China benefits farmers health, study finds
10. A new study examines how shared pathogens affect host populations
11. NYU study reveals how brains immune system fights viral encephalitis
Post Your Comments:

(Date:11/9/2015)... DUBLIN , Nov. 09, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) ...
(Date:11/4/2015)... New York , November 4, 2015 ... to a new market report published by Transparency Market ... Share, Growth, Trends and Forecast 2015 - 2022", the global ... of US$ 30.3 bn by 2022. The market is ... the forecast period from 2015 to 2022. Rising security ...
(Date:10/29/2015)... , Oct. 29, 2015   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... High Tech Association (MHTA) as one of only three ... the "Software – Small and Growing" category. The Tekne Awards ... who have shown superior technology innovation and leadership. ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... and NEW YORK , November 24, 2015 ... by Bristol-Myers Squibb in a European ... Squibb Company in which the companies will work closely ... and other areas of unmet medical need. The collaboration is ... 5, the latest LSP fund. This is the first investment ...
(Date:11/24/2015)... NEW YORK , Nov. 24, 2015 According ... today than in 2005. This is something that many doctors, ... long time. One questions remains: with fewer PSA tests being ... cancer ? Dr. David Samadi, "Despite ... cancer, the disease remains the second leading cancer cause of ...
(Date:11/23/2015)...   Ceres, Inc . (Nasdaq: CERE ), ... the fiscal year ended August 31, 2015 and provided ... --> During fiscal year 2015, Ceres ... with a better balance of yield, energy and nutrition. ... several leading crop input providers and made significant progress ...
(Date:11/23/2015)... ... 2015 , ... Shimadzu Corporation announces that it has won ... system. The award from R&D magazine recognizes Shimadzu’s Nexera UC system as one ... analytical and testing category. R&D Magazine chose the Nexera UC system because its ...
Breaking Biology Technology: